Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris
2015-005279-25Phase 2Completed
- Sponsor
- LEO Pharma
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis comparing LEO 32731 30 mg twice daily with Placebo twice daily (2 arms). Primary endpoint: PASI. Started Feb 2016; status: completed.
02
Drugs
orismilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2015-005279-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005279-25.